Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(14.29%)
AUD 0.01
(14.29%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -19.57 Million AUD | -11.75% |
| 2023 | -17.51 Million AUD | 5.72% |
| 2022 | -17.39 Million AUD | -2.14% |
| 2021 | -19.36 Million AUD | -47.16% |
| 2020 | -13.34 Million AUD | 18.78% |
| 2019 | -12.76 Million AUD | -19.62% |
| 2018 | -11.36 Million AUD | -77.96% |
| 2017 | -6.86 Million AUD | 35.09% |
| 2016 | -8.56 Million AUD | 13.2% |
| 2015 | -10.57 Million AUD | 15.61% |
| 2014 | -12.53 Million AUD | -58.87% |
| 2013 | -7.76 Million AUD | -2.18% |
| 2012 | -5.2 Million AUD | -23.67% |
| 2011 | -6.39 Million AUD | -28.44% |
| 2010 | -4.87 Million AUD | 46.13% |
| 2009 | -7.48 Million AUD | 23.9% |
| 2008 | -12.68 Million AUD | -9.92% |
| 2007 | -10.93 Million AUD | 1.82% |
| 2006 | -12.12 Million AUD | -701.51% |
| 2005 | -15.94 Million AUD | 126.98% |
| 2004 | -7.7 Million AUD | -269.48% |
| 2003 | -2.61 Million AUD | 45.8% |
| 2002 | -3.83 Million AUD | -81.62% |
| 2001 | -1.86 Million AUD | -442.06% |
| 2000 | -343.17 Thousand AUD | -328.97% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -15.02 Million AUD | 0.0% |
| 2024 FY | - AUD | -60.8% |
| 2024 Q2 | -8.44 Million AUD | 0.0% |
| 2023 FY | - AUD | 5.72% |
| 2023 Q4 | -7.72 Million AUD | 0.0% |
| 2023 Q2 | -10.69 Million AUD | 0.0% |
| 2022 Q4 | -10.43 Million AUD | 0.0% |
| 2022 Q2 | -10.13 Million AUD | 0.0% |
| 2022 FY | - AUD | -2.14% |
| 2021 FY | - AUD | -47.16% |
| 2021 Q4 | -9.83 Million AUD | 0.0% |
| 2021 Q2 | -9.6 Million AUD | 0.0% |
| 2020 Q1 | -2.88 Million AUD | 75.22% |
| 2020 FY | - AUD | 18.78% |
| 2020 Q2 | -7.54 Million AUD | -161.45% |
| 2020 Q3 | -4.06 Million AUD | 46.05% |
| 2020 Q4 | -6.23 Million AUD | -53.22% |
| 2019 Q3 | -3.58 Million AUD | 35.84% |
| 2019 Q1 | -2.79 Million AUD | 46.0% |
| 2019 Q4 | -11.63 Million AUD | -224.43% |
| 2019 FY | - AUD | -19.62% |
| 2019 Q2 | -5.59 Million AUD | -100.0% |
| 2018 Q3 | -2.58 Million AUD | 13.63% |
| 2018 Q2 | -2.99 Million AUD | -100.0% |
| 2018 FY | - AUD | -77.96% |
| 2018 Q4 | -5.17 Million AUD | -100.0% |
| 2018 Q1 | -1.49 Million AUD | 44.97% |
| 2017 Q1 | -2.06 Million AUD | 53.02% |
| 2017 Q3 | -1.36 Million AUD | 67.09% |
| 2017 Q2 | -4.13 Million AUD | -100.0% |
| 2017 FY | - AUD | 35.09% |
| 2017 Q4 | -2.72 Million AUD | -100.0% |
| 2016 Q4 | -4.4 Million AUD | -100.0% |
| 2016 Q2 | -4.16 Million AUD | -100.0% |
| 2016 Q3 | -2.2 Million AUD | 47.08% |
| 2016 Q1 | -2.08 Million AUD | 65.73% |
| 2016 FY | - AUD | 13.2% |
| 2015 FY | - AUD | 15.61% |
| 2015 Q2 | -4.5 Million AUD | -100.0% |
| 2015 Q3 | -3.03 Million AUD | 32.64% |
| 2015 Q4 | -6.06 Million AUD | -100.0% |
| 2015 Q1 | -2.25 Million AUD | 51.81% |
| 2014 Q2 | -7.82 Million AUD | -100.0% |
| 2014 FY | - AUD | -58.87% |
| 2014 Q3 | -2.33 Million AUD | 70.13% |
| 2014 Q1 | -3.91 Million AUD | -8.9% |
| 2014 Q4 | -4.67 Million AUD | -100.0% |
| 2013 Q3 | -1.79 Million AUD | 56.9% |
| 2013 Q4 | -3.59 Million AUD | -100.0% |
| 2013 Q1 | -2.08 Million AUD | 0.0% |
| 2013 FY | - AUD | -2.18% |
| 2013 Q2 | -4.16 Million AUD | -100.0% |
| 2012 FY | - AUD | -23.67% |
| 2011 FY | - AUD | -28.44% |
| 2010 FY | - AUD | 46.13% |
| 2009 FY | - AUD | 23.9% |
| 2008 Q1 | 127 Thousand AUD | 101.12% |
| 2008 FY | - AUD | -9.92% |
| 2008 Q4 | -13.1 Million AUD | -11144.72% |
| 2008 Q3 | 118.66 Thousand AUD | 104.99% |
| 2008 Q2 | -2.37 Million AUD | -1973.46% |
| 2007 FY | - AUD | 1.82% |
| 2007 Q4 | -11.36 Million AUD | -8504.24% |
| 2007 Q3 | 135.2 Thousand AUD | 103.86% |
| 2007 Q2 | -3.5 Million AUD | -3063.34% |
| 2007 Q1 | 118.3 Thousand AUD | 100.99% |
| 2006 Q3 | 190.67 Thousand AUD | 105.93% |
| 2006 Q2 | -3.21 Million AUD | -1580.14% |
| 2006 Q1 | 217.29 Thousand AUD | 101.57% |
| 2006 FY | - AUD | -701.51% |
| 2006 Q4 | -11.98 Million AUD | -6385.63% |
| 2005 Q3 | 637 Thousand AUD | 157.4% |
| 2005 Q4 | -13.82 Million AUD | -2270.86% |
| 2005 FY | - AUD | 126.98% |
| 2005 Q2 | -1.1 Million AUD | -262.16% |
| 2005 Q1 | 684.35 Thousand AUD | 106.46% |
| 2004 Q4 | -10.59 Million AUD | -1853.18% |
| 2004 Q1 | 561.87 Thousand AUD | 111.7% |
| 2004 FY | - AUD | -269.48% |
| 2004 Q3 | 604.41 Thousand AUD | 136.57% |
| 2004 Q2 | -1.65 Million AUD | -394.16% |
| 2003 Q4 | -4.8 Million AUD | -936.43% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q2 | -1.27 Million AUD | -625.94% |
| 2003 FY | - AUD | 45.8% |
| 2003 Q3 | 574.13 Thousand AUD | 145.03% |
| 2002 FY | - AUD | -81.62% |
| 2001 FY | - AUD | -442.06% |
| 2000 FY | - AUD | -328.97% |
| 1999 FY | - AUD | -11494.2% |
| 1998 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -269.087% |
| Acrux Limited | -7.93 Million AUD | -146.773% |
| Race Oncology Limited | -14.2 Million AUD | -37.795% |
| Biome Australia Limited | -1.57 Million AUD | -1140.082% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | -40.607% |
| BTC Health Limited | 1.05 Million AUD | 1954.624% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | -73.203% |
| CSL Limited | 4.73 Billion AUD | 100.414% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 56.164% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 137.737% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 288.633% |
| Hexima Limited | -995.54 Thousand AUD | -1865.922% |
| Immutep Limited | -42.87 Million AUD | 54.352% |
| Memphasys Limited | -3.3 Million AUD | -491.694% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 109.822% |
| Noxopharm Limited | -5.94 Million AUD | -229.184% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -172.369% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 56.868% |
| Starpharma Holdings Limited | -12.57 Million AUD | -55.614% |
| Tissue Repair Ltd | -5.77 Million AUD | -238.903% |
| Biotron Limited | -5.04 Million AUD | -288.321% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -1243.591% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -557.872% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 46.293% |
| Patrys Limited | -3.49 Million AUD | -460.445% |
| Orthocell Limited | -11.68 Million AUD | -67.549% |
| Imugene Limited | -147.97 Million AUD | 86.774% |
| PYC Therapeutics Limited | -38.11 Million AUD | 48.655% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -148.14% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -96.695% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -121.57% |
| Nanollose Limited | -1.14 Million AUD | -1604.991% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -2616.614% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -989.56% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -329.24% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -594.492% |
| Nyrada Inc. | -4.59 Million AUD | -325.821% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 185.22% |
| Dimerix Limited | -24.95 Million AUD | 21.584% |
| PharmAust Limited | -9.45 Million AUD | -107.069% |
| AnteoTech Limited | -11.57 Million AUD | -69.144% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 69.675% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 8.347% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -503.594% |
| Actinogen Medical Limited | -12.92 Million AUD | -51.469% |
| Immuron Limited | -6.19 Million AUD | -216.061% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -931.392% |